References
O'Hagan, P. & Farkas, C. Bringing pharma R.&D back to health. Bain Brief [online], (2009).
Lindgardt, Z., Reeves, M. & Wallenstein, J. Waking the giant: business model innovation in the drug industry. In Vivo 26, 1–6 (2008).
Garnier, J. Rebuilding the R.&D engine in big pharma. Harvard Bus. Rev. 86, 68–76 (2008). A candid assessment by the former CEO of GlaxoSmithKline of the downsides of the industry's process culture.
Angell, M. The Truth about Drug Companies: How They Deceive Us and What to do About It. (Random House Trade Paperbacks, New York, 2005).
Chertkow, J. Trends in pharmaceutical portfolio management: strategies to maintain profitability despite adversity. Datamonitor [online] (2008).
Murray, A., Berndt, E. R. & Cutler, D. M. Prescription drug spending trends in the United States: looking beyond the turning point. Health Affairs w151–w160, (2008).
EvaluatePharma Alpha World Preview 2014. Evaluate Pharma report (2009).
Goodman, M. Market watch: Pharma industry performance metrics: 2007–2012E. Nature Rev. Drug Discov. 7, 795 (2008).
Mathieu, M. P., ed. Parexel's Bio/Pharmaceutical R&D Statistical Sourcebook 2008/2009. (Parexel International Corporation, Waltham, 2008).
Pisano, G. P. Science Business: the Promise, the Reality, and the Future of Biotech. (Harvard Business School Press, Boston, 2006). An insightful retrospective on the biotech industry, and the reasons why it has not yet lived up to its promises.
DiMasi, J. A. & Grabowski, H. G. The cost of biopharmaceutical R&D: Is biotech different? Manage. Decis. Econ. 28, 469–479 (2007). A contemporary assessment of the costs to discover, develop and launch new molecular entities.
Kola, I. The state of innovation in drug development. Clin. Pharmacol. Ther. 83, 227–230 (2008).
Cohen, F. J. Macro trends in pharmaceutical innovation. Nature Rev. Drug Discov. 4, 78–84 (2005).
Lichtenberg, F. R. The impact of new drug launches on longevity: evidence from longitudinal, disease-level data from 52 countries, 1982–2001 Int. J. Health Care Finance Econ. 5, 47–43 (2005).
Kimball, T. R., McCoy, C. E., Khoury, P. R., Daniels, S. R. & Dolan, L. M. Obesity, diabetes damage young arteries, could shorten life. News release, American Heart Association website [online] (2009).
KMR Group. Pharmaceutical Benchmarking Forum [online] (2009).
Booth, B. & Zemmil, R. Prospects for productivity. Nature Rev. Drug Discov. 3, 451–456 (2004). Booth and Zemmil framed the issue of productivity in the pharmaceutical industry and provide a qualitative discussion of some of the drivers and potential solutions.
Hu, M., Schultz, K., Sheu, J. & Tschopp, D. The innovation gap in pharmaceutical drug discovery & new models for R&D success. [online], (2007).
Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nature Rev. Drug Discov. 3, 711–715 (2004). This article provides an in-depth analysis of attrition by phase and therapy area, and offers a scientific approach to reduce Phase II and Phase III attrition rates.
Innovation or Stagnation? Challenge and Opportunity on the Critical Path to New Medical Products[online], (2004). A seminal paper on the hurdles that must be overcome to reverse the decline in R&D productivity.
Peck, R. W. Driving earlier clinical attrition: if you want to find the needle, burn down the haystack. Considerations for biomarker development. Drug Discov. Today 12, 289–294 (2007).
Little, J. D. C. A proof of the queuing formula L = λ W. Oper. Res. 9, 383–387 (1961).
Bunch, P. R. & Schacht, A. L. Modeling resource requirements for pharmaceutical R.&D. Res. Technol. Manage. 45, 48–56 (2002).
Deloitte Touche Tohmatsu. Threading the talent needle: what global executives are saying about people and work. [online], (2009).
See AlsoR&D Inadequacies in IndiaPricewaterhouseCoopers. The changing dynamics of pharma outsourcing in Asia: are you readjusting your sights? [online], (2008).
Danzon, P. M., Nicholson S. & Pereira N. S. Productivity in pharmaceutical-biotechnology R&D: the role of experience and alliances. J. Health Econ. 24, 317–339 (2005).
Gregson, N., Sparrowhawk, K., Mauskopf, J. & Paul, J. Pricing medicines: theory and practice, challenges and opportunities. Nature Rev. Drug Discov. 4, 121–130 (2005).
Woodco*ck, J. The prospects for “personalized medicine” in drug development and drug therapy. Clin. Pharmacol. Ther. 1, 164–169 (2007).
DiMasi, J. A. The value of improving the productivity of the drug development process: faster times and better decisions. Pharmacoeconomics 20, 1–10 (2002).
Pyzdek, T. The Six Sigma Handbook: The complete guide for greenbelts, blackbelts, and managers of all levels. 2nd revised edition (McGraw-Hill, New York, 2003).
Goldratt, E. M. & Cox J. The goal: a process of ongoing improvement. Third edition. (Gower Publishing, Aldershot, 2004).
Maca, J., Bhattacharya, S., Dragalin, V, Gallo, P, Krams, M. Adaptive seamless phase II/III designs—background, operational aspects, and examples. Drug Inf. J. 4, 463–473 (2006).
Kramer, J. A., Sagart, J. E. & Morris, D. L. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. Nature Rev. Drug Discov. 6, 636–649 (2007).
Hopkins, A. L. & Groom, C. R. The druggable genome. Nature Rev. Drug Discov. 1, 727–730 (2002).
Grenet, O. Significance of the human genome sequence to drug discovery. Pharmacogenomics J. 1, 11–12 (2001).
Horton, J. D., Cohen, J. C. & Hobbs, H. H. PCSK9: a convertase that coordinates LDL catabolism. J. Lipid Res. S172–S177 (2009).
Abifadel, M. et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nature Genet. 34, 154–156 (2003).
Cohen, J. C., Boerwinkle, E., Mosley, Jr., T. H. & Hobbs, H. H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354, 1264–1272 (2006).
Cao, G., Qian, Y. W., Kowala, M. C. & Konrad, R. J. Further LDL cholesterol lowering through targeting PCSK9 for coronary artery disease. Endocrine, Metabolic & Immune Disorders – Drug Targets. 8, 238–243 (2008).
Chan, J.C. et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc. Natl Acad. Sci. USA 106, 9820–9825 (2009).
Shepherd, J. et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes. Diabetes Care 29, 1220–1226 (2006).
Drenth, J. P. H. & Waxman, S. G. Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disorders. J. Clin. Invest. 117, 3603–3609 (2007).
Krafte, D. S. & Bannon, A. W. Sodium channels and nociception: recent concepts and therapeutic opportunities. Curr. Opin. Pharmacol. 8, 50–56 (2008).
Bonabeau, E. N., Bodick, N. & Armstrong, R. W. A more rational approach to new-product development. Harvard Bus. Rev. 86, 96–102 (2008). A review of Eli Lilly's Chorus model of early drug development and FIPNet strategy.
Cuatrecasas, P. Drug discovery in jeopardy. J. Clin. Invest. 116, 2837–2842 (2006). A frank analysis by one of the most successful R&D leaders of problems that have fostered the current innovation crisis.
